Bimekizumab (Bimzelx, UCB) Shows Lasting Efficacy in Phase 3 PsA Study
Bimekizumab-bkzx (Bimzelx, UCB) showed sustained control of inflammation and deep efficacy in adults with active psoriatic arthritis (PsA) for up to three years, according to research presented at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain.